Quick Acting Antibiotic Lends Promise To Destiny's Future
Executive Summary
Destiny Pharma's US NIAID-funded clinical study yields positive results for the novel quick-acting antibacterial exeporfinium chloride.
You may also be interested in...
Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC
The latest drug development news and highlights from our FDA Performance Tracker.
'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery
Destiny Pharma Ltd., a small UK antibiotic developer, and its lead "rapidly bactericidal" product XF-73, has placed itself firmly on the radar in the US. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is sponsoring and funding a clinical trial which is expected to complete in the coming weeks. If successful, XF-73 will be filed for the prevention of post-surgical Staphylococcal infections, a completely new indication. CEO Dr Bill Love explained to Scrip why the interest in Destiny's child.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.